Meng Wu investigates how tumor-immune microenvironments and immunometabolism govern responses to checkpoint therapy and radiotherapy. Work links gut microbiota metabolites to antitumor immunity and develops blood-based indices and multi-omic analyses for patient stratification across solid and hematologic cancers.